Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Solcera
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Solcera** is a topical medicinal product containing 5% potassium hydroxide (KOH) solution, indicated for the treatment of mild to moderate actinic keratosis in adults with an intact immune system. It is applied lesion-directed twice daily for 28 days using product-specific applicators, functioning as a keratolytic agent that chemically destroys precancerous skin lesions through localized tissue dissolution. Currently under clinical investigation, including the KOHDIAK phase 3 trial (NCT04552327) comparing its efficacy and safety against placebo and diclofenac 3% gel (Solaraze), with primary endpoints focused on complete clearance of lesions.[5][7][9][15]
- Brand names
- Solcera
Beyond the preview
Go deeper on Solcera.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solcera.